
Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxORkMtVmt5U1Z1VVVZa2VhRk44Y1huQTFJZHY5bWhCRkhFMkhHS29ILTE2ek1nZjRueEhNSFVHdXRYS2VnQlMzV2V2a2dPYWFqMi1tMmowSHhzZ0pCTWdYSnowSTlfV2l3SWxHSXFFY1ZrSnJSZ0F5VkNVcGc0M2hPNXREZjVPYktHdFlMbEtzclZpSnl2aS1JRGFqUE9lNFk?oc=5" target="_blank">Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy</a>&nbsp;&nbsp;<font color="#6f6f6f">AstraZeneca</font>
